Transformation Capital leads $21M investment in Solstice, enabling pharma brands to slash medical, legal, and regulatory marketing review cycles from weeks to less than 48 hours

转型资本领投Solstice 2100万美元，助力制药品牌将医学、法律和监管营销审查周期从数周缩短至不到48小时。

NEW YORK

纽约

,

，

May 28, 2026

2026年5月28日

/PRNewswire/ --

/PRNewswire/ --

Solstice

至日

, the AI-native marketing agency accelerating pharma commercialization, today announced it has raised $21 million in Series A funding led by

，这家以人工智能为核心的营销机构，正在加速制药业的商业化进程，今天宣布它已经筹集了2100万美元的A轮融资，由

Transformation Capital

转型资本

with participation from

参与者包括

Twelve Below

十二度以下

,

，

Virtue Ventures

美德创投

and others. The round brings total funding to approximately $25 million. The capital will fuel go-to-market expansion, accelerate product development and enable Solstice to grow its team across product and customer-facing functions. Few business challenges are as high-stakes and time-sensitive as commercializing a new drug or medical product..

和其他投资者。此轮融资使总融资额达到约 2500 万美元。这笔资金将推动市场扩展、加速产品开发，并让 Solstice 能够在产品和客户导向的职能部门扩充团队。很少有商业挑战像推出新药或医疗产品那样充满高风险且时间紧迫。

Biopharma companies are projected to spend more than

生物制药公司预计将会花费超过

$100 billion on commercialization efforts

1000亿美元用于商业化努力

. Yet, the process of transforming clinical evidence into compliant marketing campaigns has barely changed over the past decades. A single marketing asset, even something as routine as an email, often takes three

然而，将临床证据转化为合规的营销活动的过程在过去的几十年里几乎没有改变。一个单一的营销素材，即使是像电子邮件这样常规的内容，往往也需要三个...

months

月份

to move through medical, legal and regulatory (MLR) review. With shrinking patent exclusivity windows, every additional month of delay means fewer patients receiving a therapeutic.

通过医学、法律和监管 (MLR) 审查。随着专利独占期的缩短，每多延迟一个月，就意味着接受治疗的患者减少。

'We built Solstice to help life sciences teams bring therapeutics to market faster by unifying content creation, medical review and performance insights in a single AI-native system that generates beautiful content, grounds every claim in clinical evidence before MLR review and measures what content will actually move the needle in driving physician and patient action,' said Aris Saxena, co-founder and CEO of Solstice.

“我们构建Solstice是为了帮助生命科学团队更快地将治疗方案推向市场，通过在一个原生AI系统中统一内容创作、医学审查和绩效洞察，生成精美的内容，确保每个主张在MLR审查之前都基于临床证据，并衡量哪些内容真正能够推动医生和患者采取行动，”Solstice联合创始人兼首席执行官Aris Saxena表示。

'Our customers used to run three review cycles per asset; now they run one or two at most, and content that used to take months goes out in 10 days. Most importantly, they create more personalized, higher-performing content that helps them compete in increasingly crowded biopharma markets.'.

“我们的客户过去每项资产要进行三次审查周期；现在最多只进行一两次，过去需要数月的内容现在十天内就能发布。最重要的是，他们创建了更加个性化、更高绩效的内容，帮助他们在日益拥挤的生物制药市场中竞争。”

Solstice pairs AI-native technology with in-house subject-matter experts to replace traditional workflows among marketing agencies, regulatory teams and in-house marketers. The platform ingests a brand's clinical data, FDA documents and approved literature to build a grounded understanding of the product to quickly generate digital campaigns, programmatic ads and patient and healthcare provider communications.

Solstice 将原生人工智能技术与内部主题专家相结合，取代营销机构、监管团队和内部营销人员之间的传统工作流程。该平台吸收品牌的临床数据、FDA 文件和已批准的文献，以建立对产品的扎实理解，从而快速生成数字营销活动、程序化广告以及患者和医疗保健提供者的沟通材料。

Every asset is created and reviewed using a combination of Solstice's proprietary pharmaceutical marketing models as well as the company's in-house experts for both compliance and taste, and is scored on its likelihood of MLR approval for review before it reaches the regulatory team. Solstice then measures content performance to predict the highest-performing assets and produce novel content that drives physician and patient engagement.

每项资产的创建和审查均结合了Solstice专有的医药营销模型以及公司内部合规和品味专家的意见，并在其提交监管团队之前根据其获得MLR批准的可能性进行评分。随后，Solstice会衡量内容表现，以预测表现最佳的资产并制作推动医生和患者参与的创新内容。

The result is a faster path to attributable, compliant content without sacrificing the expertise pharma brands require..

结果是更快地获得可归属的、合规的内容，同时不会牺牲制药品牌所需的专长。

'Before Solstice, getting a single marketing asset through MLR could take weeks of back-and-forth that delayed launch and healthcare provider outreach,' said Kristine Saffrin, marketing director, Alexion Pharmaceuticals. 'Now we move from draft to approved in days, which means our team can actually deliver on the personalization and pace a modern brand demands.'.

“在Solstice之前，通过MLR获取单一营销素材可能需要数周的反复沟通，这会延误上市时间和医疗保健提供者的推广工作，”Alexion制药公司市场总监Kristine Saffrin表示。“现在我们从草稿到批准只需几天时间，这意味着我们的团队实际上可以满足现代品牌所需的个性化和节奏。”

Solstice customers launch campaigns 12 times faster than they would via traditional agencies, enabling content to move from concept to MLR submission in under 48 hours and be market-ready in roughly 10 days. As a result, teams are producing nearly three times more high-quality, tasteful and effective content per quarter and reducing the average number of MLR reviews per asset from 3.2 rounds to 1.2 rounds..

Solstice 的客户发起活动的速度比通过传统机构快 12 倍，使内容能够在 48 小时内从概念提交到 MLR，并在大约 10 天内准备就绪进入市场。结果，团队每个季度产出的高质量、优雅且有效的内容增加了近三倍，同时还将每个资产的平均 MLR 审核次数从 3.2 轮减少到 1.2 轮。

'Bringing a new drug to market is one of the most valuable and heavily regulated processes in healthcare, yet the commercialization workflow has barely changed in decades,' said Vinay Shah, Partner and Founding Team Member at Transformation Capital. 'Solstice is using AI to fix that — helping pharma brands move faster without compromising compliance.

“将新药推向市场是医疗保健领域最有价值且监管最严格的过程之一，但商业化工作流程几十年来几乎没有什么变化，”Transformation Capital 的合伙人兼创始团队成员 Vinay Shah 表示。“Solstice 正在利用人工智能解决这个问题——帮助制药品牌在不牺牲合规性的情况下加速发展。”

Customers are already seeing real results via faster reviews and meaningful cost savings. We're thrilled to lead this round and partner with the Solstice team.'.

客户已经通过更快的审核和有意义的成本节约看到了实际效果。我们很高兴能够主导这一轮并与Solstice团队合作。

The Series A follows a year of rapid commercial growth for the company, which now serves over a dozen pharmaceutical companies, including several of the top 20 pharmaceutical brands across therapeutic areas, including oncology, immunology and metabolic diseases.

A轮融资是在该公司经历了快速商业增长的一年之后进行的，该公司目前为十多家制药公司提供服务，其中包括多个治疗领域（包括肿瘤学、免疫学和代谢疾病）排名前20的制药品牌中的几家。

To learn more or request a demo, visit

要了解更多信息或请求演示，请访问

www.solsticehealth.co

www.solsticehealth.co

.

。

About Solstice:

关于至日：

Solstice is the AI-native marketing agency for pharma brands. The company pairs AI technology with in-house experts to generate, review and activate compliant marketing content at speed, replacing the traditional handoffs between agencies, regulatory teams and in-house marketers. Headquartered in New York, Solstice is backed by leading investors including Transformation Capital, Twelve Below, Virtue Ventures, Ford Street Ventures, Go Global Ventures, Cory Capital and others.

Solstice 是一家专注于制药品牌的 AI 原生营销机构。该公司将人工智能技术与内部专家相结合，快速生成、审核并激活合规的营销内容，取代了传统代理机构、监管团队和内部营销人员之间的交接流程。总部位于纽约的 Solstice 获得了包括 Transformation Capital、Twelve Below、Virtue Ventures、Ford Street Ventures、Go Global Ventures、Cory Capital 等领先投资者的支持。

For more information, visit .

欲了解更多信息，请访问 。

https://www.solsticehealth.co/

https://www.solsticehealth.co/

.

。

Contact:

联系人：

BAM by BIG for Solstice

BIG为至日设计的BAM

[email protected]

电子邮件地址

SOURCE Solstice Health

来源：Solstice Health

21

21

%

%

more press release views with

更多新闻发布视图与

Request a Demo

请求演示